Shared on 30 Oct 25
Fair value Decreased 2.87%Analysts have lowered their price target for PROCEPT BioRobotics from $62.70 to $60.90, citing broad MedTech market volatility and anticipated stock fluctuations. This comes despite expectations of healthy Q3 financial performance.
Shared on 16 Oct 25
Fair value Decreased 4.42%Clinical Adoption And Global Expansion Will Redefine Healthcare
Analysts have updated their price target for PROCEPT BioRobotics, lowering it from $64 to $50 per share. They cite expectations for healthy revenue, but also note increased market volatility and cautious investor sentiment in the MedTech sector.
Shared on 08 Aug 25
Fair value Decreased 4.41%Clinical Adoption And Global Expansion Will Redefine Healthcare
The modest reduction in PROCEPT BioRobotics’ consensus price target to $65.75 reflects a slight downward revision in the company’s future P/E multiple, while profitability remains stable. What's in the News Raised full-year 2025 revenue guidance to $325.5 million, representing 45% year-over-year growth; projected net loss for 2025 is $83.5 million.
Shared on 01 May 25
Fair value Decreased 31%Clinical Adoption And Global Expansion Will Redefine Healthcare
Shared on 24 Apr 25
Fair value Decreased 0.53%US Medicare Coverage And Aquablation Trials Will Expand Patient Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 3.18%US Medicare Coverage And Aquablation Trials Will Expand Patient Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
US Medicare Coverage And Aquablation Trials Will Expand Patient Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 9.95%US Medicare Coverage And Aquablation Trials Will Expand Patient Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 23%US Medicare Coverage And Aquablation Trials Will Expand Patient Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.